A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).

A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).

The impact of the COVID-19 pandemic on rates of molecular testing used by community oncologists who care for patients with urothelial cancer.

A discussion on molecular testing in the community and recommendations that can address barriers.

An overview of the types of health care professionals who may help manage patients with metastatic urothelial cancer throughout their disease course.

The significance of using broad genomic profiling tests to help detect promising biomarkers in metastatic urothelial cancer.

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa explain how they would establish goals of therapy and a treatment algorithm for a patient who presents with metastatic urothelial cancer.

Factors that impact the selection of immunotherapy vs chemotherapy for frontline metastatic urothelial cancer.

Current recommendations for repeat testing in patients with relapsed metastatic urothelial cancer.

Strategies that can be used to counsel patients on molecular testing for FGFR mutations and what to expect from treatment with erdafitinib.

What oncologists need to know about the management of ocular toxicity for patients with metastatic urothelial cancer receiving FGFR-targeted therapy.

An overview of adverse events commonly associated with FGFR-targeted therapies such as erdafitinib.

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa consider how the urology field will likely advance with more interest in genomic profiling in metastatic urothelial cancer and novel therapies in the pipeline.